Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Antifactor (F)XI/FXIa anticoagulants under development include antisense oligonucleotides, monoclonal antibodies, and small molecules. They do not require routine monitoring, but knowledge of their impact on coagulation tests is essential in view of their expected widespread use. A concentration-dependent prolongation of activated partial thromboplastin time has been shown but varies according to reagents, and the lack of comprehensive data makes interpretation of this test difficult. Measurement of FXI clotting activity is relevant only in case of treatment with antisense oligonucleotides. Measurement of contact pathway factors, if required, should be performed after multiple dilutions of the plasma sample to overcome any inhibitory effect of the anticoagulant. All other tests used in clinical trials (FXIa, FXI antigenic method, and specific thrombin generation assay) are not implemented in clinical laboratories. More comprehensive information on the effect of anti-FXI/FXIa anticoagulants on coagulation tests is urgently needed to anticipate the use of these drugs once they are approved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtha.2025.02.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Viscoelastic Haemostatic Assay Landscape in Queensland, Australia: An Analysis of Use, Indications and Integration.
Emerg Med Australas
October 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: Viscoelastic haemostatic assays (VHAs) guide transfusion decisions in bleeding patients. We assessed testing volumes, clinical indications and patient characteristics in a statewide population in Australia.
Methods: This retrospective study included all patients who underwent rotational thromboelastometry (ROTEM) or thromboelastography (TEG) across Queensland Health hospitals (1 January 2019 to 15 April 2025), using data from AUSLAB, the statewide laboratory information system and surveyed all hospitals for VHA device availability.
Plasma Arginine Vasopressin and Serum Copeptin Concentrations at Rest and After Osmotic- and Non-Osmotic-Based Stimulation Tests in Dogs.
J Vet Intern Med
September 2025
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Background: Serum copeptin (sCoP) is used as a surrogate for plasma arginine vasopressin (pAVP) measurement in humans.
Objective: To measure pAVP and sCoP at rest and after osmotic- and non-osmotic stimulation testing in dogs.
Animals: Eight young castrated/spayed healthy research Beagles, eight young intact dogs, and eight old neutered healthy client-owned dogs.
Viscoelastic testing in patients with very rare bleeding disorders of secondary hemostasis, a scoping review.
Thromb Res
September 2025
Department of Hematology, Radboud university medical centre, Nijmegen, the Netherlands; Hemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, the Netherlands. Electronic address:
Introduction: Very rare bleeding disorders (VRBDs) are hereditary disorders which cause increased risk of bleeding. In general, VRBDs consists of rare platelet function disorders, very rare coagulation factor deficiencies (other than Factor (F) VIII or FIX) and disorders of the fibrinolytic pathway. The rarity of these disorders along with the scarcity of specialized hemostasis laboratories capable to perform the necessary diagnostic tests, results in significant challenges in diagnosing and monitoring patients with VRBD.
View Article and Find Full Text PDFPlasma transfusion practice: A five-year audit of plasma transfusion at 23 hospitals.
Transfusion
September 2025
Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Canada.
Background: There is limited high-quality evidence to guide plasma transfusion, and plasma transfusion practices remain variable.
Study Design And Methods: This is a retrospective cohort study that included adult medical and intensive care unit (ICU) inpatients (age ≥ 18 years) admitted to 23 hospitals in Canada between January 1, 2017, and December 31, 2022, when both whole blood derived (~290 mL) and apheresis plasma (~250 mL) were available for transfusion. Nine additional hospital sites with missing plasma data or coagulation testing were excluded.
Novel antibacterial, antioxidant, and anti-inflammatory aminated chitosan hybrid quinoline Schiff base as multi-target agent: Design, molecular docking, and toxicity assessment.
Carbohydr Polym
November 2025
Polymer Institute of the Slovak Academy of Sciences, Dúbravská Cesta 9, 845 41 Bratislava, Slovakia; Polymer Materials Research Department, Advanced Technology and New Materials Research Institute (ATNMRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab Ci
This study involves the synthesis of a novel 7-ethoxy-3-formyl-2-morpholino quinoline (MQ) derivative, which was hybridized with aminated chitosan (AMCH) to yield a new AMCH-MQ Schiff base. Structural characterization via H NMR, FTIR, electronic spectra, XRD, and TGA confirmed successful hybridization. Ion exchange capacity decreased from 28.
View Article and Find Full Text PDF